|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1991-9-16
|
|
pubmed:abstractText |
Topoisomerase II is now viewed as an important cellular target of antitumor drugs including both DNA intercalators (m-AMSA, ellipticine and Adriamycin) and the nonintercalator epipodophyllotoxin derivatives (VP-16 and VM-26). Topoisomerase I is also shown to be the cellular target of camptotecin. These drugs targeting topoisomerase have been used to establish a relationship between drug-induced cleavable complex formation and cytotoxicity. Mechanistically oriented screening based on the identification of these chemotherapeutic targets have identified a number of antitumor agents that induce topoisomerases mediated DNA cleavage. The new antitumor drugs targeting topoisomerases are reviewed.
|
|
pubmed:language |
jpn
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0385-0684
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1550-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1651681-Amsacrine,
pubmed-meshheading:1651681-Animals,
pubmed-meshheading:1651681-Antibiotics, Antineoplastic,
pubmed-meshheading:1651681-DNA Topoisomerases, Type II,
pubmed-meshheading:1651681-Diterpenes,
pubmed-meshheading:1651681-Doxorubicin,
pubmed-meshheading:1651681-Etoposide,
pubmed-meshheading:1651681-Leukemia P388,
pubmed-meshheading:1651681-Mice
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
[Antitumor agents targeting mammalian topoisomerases].
|
|
pubmed:affiliation |
Tokyo Research Laboratories, Kyowa Hakko Co. Ltd., Japan.
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review
|
